Baseline MRI markers and clinical outcomes during anti-amyloid β therapy: A real-world study in a Japanese dementia center

Kujuro Y, Saito M, Maruko M, Kamiyama K, Nakano A, Qian E, Okamura T, Ito D, Kageyama T, Sugiyama I, Ishihara E, Kuwahara T, Moritani K, Katai H, Hattori H

Abstract

Importance Predictors of decline and of amyloid-related imaging abnormalities (ARIA) during anti-amyloid β therapy in routine care are undefined. Objective To identify baseline predictors of cognitive, functional, and safety outcomes. Design, setting, and participants Retrospective cohort of 161 consecutive patients initiating anti-amyloid β therapy at a Tokyo dementia center, 2024 to 2026 (lecanemab, 89; donanemab, 72). Exposures Lecanemab or donanemab. Main outcomes and measures Change in MMSE and CDR-Sum of Boxes (CDR-SB); baseline medial temporal atrophy (VSRAD Z score), amyloid PET burden, and microbleeds; ARIA. Results With lecanemab, MMSE and CDR-SB declined significantly at every assessment (CDR-SB +0.79, +1.10, +1.60 at 6, 12, 18 months); memory and orientation declined while language was preserved. Greater baseline medial temporal atrophy was associated with greater 12-month CDR-SB worsening (r = 0.39; P = .01; n = 40); patients in the most severe standard category (Z ≥ 3) worsened by 2.62 versus 0.64 points (adjusted β = +2.18; P < .001). Atrophy was associated with older age (r = 0.19; P = .03) and with baseline memory-related measures - ADAS-Cog score (r = 0.32; P < .001) and the MMSE subdomains of delayed recall (β = -0.25; P = .006) and time orientation (β = -0.30; P = .04) - but not MMSE total score. Amyloid PET burden showed no significant association at most time points. All ARIA events were asymptomatic; ARIA-H occurred in 6 of 25 with microbleeds versus 3 of 136 without (odds ratio, 14.0; P < .001). Donanemab follow-up was 6 months. Conclusions and relevance Baseline medial temporal atrophy was associated with functional decline and microbleeds with ARIA-H. Pretreatment MRI may provide prognostic and safety information during anti-amyloid β therapy.

Abstract of "Baseline MRI markers and clinical outcomes during anti-amyloid β therapy: A real-world study in a Japanese dementia center" by Kujuro Y, Saito M, Maruko M et al., https://doi.org/10.1016/j.tjpad.2026.100686, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.

Record

Archive ID
doi:10.1016/j.tjpad.2026.100686
Published
Oct 17, 2026
Venue
The journal of prevention of Alzheimer's disease
DOI
10.1016/j.tjpad.2026.100686
PubMed
42892274
PMC
PMC13696334
License
CC-BY
Provenance
europepmc

Topics